NeoPhore Ltd.

https://www.neophore.com

LinkedIn: https://www.linkedin.com/company/neophore-ltd

NeoPhore, UK is focused on the discovery and development of novel small molecule therapies to treat cancer through stimulation of the immune system. Generation of cancer neoantigens in tumours can be exploited by the patients’ immune system to overcome natural defence mechanisms in cancer. The Company’s approach targets the DNA mismatch repair (MMR) pathway, which has been proven to promote neoantigen creation and subsequent immunity against numerous cancers. Using these insights, NeoPhore aims to generate next-generation immuno-oncology therapeutics to improve clinical outcomes for cancer patients. NeoPhore was spun-out of the University of Turin and PhoreMost Ltd by the CRT Pioneer Fund. *

	Start	2017-11-15 established (s-off)
	Predecessor	PhoreMost Ltd.
	Industry	cancer immunotherapy (immuno-oncology, I-O)
	Industry 2	small-molecule cancer drug
	Person	Shih, Michael (NeoPhore 202412– CEO before Kite Pharma + Biogen + Sanofi + Epizyme + Forest Labs + Eisai)
	Person 2	James, Robert (SIxth Element Capital 2010– Managing Partner + Co-Founder before DFJ Esprit + Prelude Ventures + CRT)

	Region	Altrincham, Greater Manchester
	Country	United Kingdom (GB)
	Street	1 Ashley Road 3rd Floor
	City	WA14 2DT Altrincham, Cheshire
	Tel	+44-330-128-9990
		Address record changed: 2025-01-23

Basic data	Employees	n. a.

		* Document for »About Section«: NeoPhore Ltd.. (12/16/24). "Press Release: NeoPhore Appoints Michael Shih as Chief Executive Officer". London.

		Record changed: 2025-03-16